MICARDIS Rx

Indications for MICARDIS:

Cardiovascular (CV) risk reduction in patients ≥55 years of age at high risk of developing major CV events who are unable to take ACE inhibitors.

Adult:

80mg once daily. Monitor BP; adjustments to meds that lower BP may be needed.

Children:

Not established.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Boxed Warning:

Fetal toxicity.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting therapy or monitor closely. Severe CHF. Biliary obstruction. Hepatic or renal impairment. Renal artery stenosis. Dialysis (monitor for orthostatic hypotension). Neonates. Pregnancy: avoid. Nursing mothers: not recommended.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).

Interactions:

See Contraindications. Concomitant ACE inhibitors (eg, ramipril): not recommended. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Hyperkalemia with K⁺ supplements, K⁺ sparing diuretics, K⁺ containing salt substitutes. May potentiate digoxin. Monitor lithium levels. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted.

Adverse Reactions:

Back pain, upper respiratory tract infection, sinusitis, diarrhea, pharyngitis, angioedema; intermittent claudication, skin ulcer; rare: rhabdomyolysis.

How Supplied:

Tabs—3 x 10 (blister cards)

Indications for MICARDIS:

Hypertension.

Adult:

Individualized. Not volume-depleted: initially 40mg once daily; usual range 20–80mg/day. Salt/volume depleted: monitor closely or consider reduced dose. May add diuretic if insufficient response at 80mg/day.

Children:

Not established.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Boxed Warning:

Fetal toxicity.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting therapy or monitor closely. Severe CHF. Biliary obstruction. Hepatic or renal impairment. Renal artery stenosis. Dialysis (monitor for orthostatic hypotension). Neonates. Pregnancy: avoid. Nursing mothers: not recommended.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).

Interactions:

See Contraindications. Concomitant ACE inhibitors (eg, ramipril): not recommended. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Hyperkalemia with K⁺ supplements, K⁺ sparing diuretics, K⁺ containing salt substitutes. May potentiate digoxin. Monitor lithium levels. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted.

Adverse Reactions:

Back pain, upper respiratory tract infection, sinusitis, diarrhea, pharyngitis, angioedema; rare: rhabdomyolysis.

How Supplied:

Tabs—3 x 10 (blister cards)